Literature DB >> 3753395

Effect of calmodulin antagonists on hypoxia and reoxygenation damage in isolated rabbit hearts.

A Beresewicz, E Karwatowska-Kryńska.   

Abstract

The effect of calmodulin antagonists trifluoperazine (2.5 X 10(-7) M and 2.5 X 10(-6) M) and R 24571 (10(-8) M and 10(-7) M) on Langendorff-perfused rabbit hearts subjected to 180 min hypoxia and 30 min reoxygenation was studied. Coronary flow, force of contraction, oxygen consumption and release of lactate, noradrenaline and LDH were measured. Both drugs were found to reduce some of the deleterious consequences of hypoxia, i.e., they caused: marked reduction in the hypoxic LDH release; reduction in hypoxic contracture; increased recovery of active tension, oxygen consumption and coronary flow upon reoxygenation as compared to those in the untreated controls. The drugs prevented reoxygenation-induced LDH release in the drug-pretreated hearts and had no effect when given only during reoxygenation. This suggests that the drugs do not prevent reoxygenation damage as such, but only some changes developing during hypoxia, which make myocardium vulnerable to the reoxygenation damage. Although other interpretations are possible (e.g., the effects are related to the membrane stabilizing action of the drugs), our data are consistent with the hypothesis that a calmodulin-sensitive process is involved in the hypoxia damage of the myocardium.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3753395     DOI: 10.1007/bf01907414

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN: 0300-8428            Impact factor:   17.165


  39 in total

1.  Calmodulin stimulates human platelet phospholipase A2.

Authors:  P Y Wong; W Y Cheung
Journal:  Biochem Biophys Res Commun       Date:  1979-09-27       Impact factor: 3.575

2.  Selective inhibitors of Ca2+-binding modulator of phosphodiesterase produce vascular relaxation and inhibit actin-myosin interaction.

Authors:  H Hidaka; T Yamaki; T Totsuka; M Asano
Journal:  Mol Pharmacol       Date:  1979-01       Impact factor: 4.436

3.  Phospholipase A activity of highly enriched preparations of cardiac sarcolemma from hamster and dog.

Authors:  R C Franson; D C Pang; D W Towle; W B Weglicki
Journal:  J Mol Cell Cardiol       Date:  1978-10       Impact factor: 5.000

4.  Phosphorylation and dephosphorylation of phosphorylase kinase in the perfused rat heart.

Authors:  T E McCullough; D A Walsh
Journal:  J Biol Chem       Date:  1979-08-10       Impact factor: 5.157

5.  A fluorometric assay for subnanogram concentrations of adrenaline and noradrenaline in plasma.

Authors:  J F O'Hanlon; H C Campuzano; S M Horvath
Journal:  Anal Biochem       Date:  1970-04       Impact factor: 3.365

6.  Inhibition of oxidative phosphorylation in ascites tumor mitochondria and cells by intramitochondrial Ca2+.

Authors:  A Villalobo; A L Lehninger
Journal:  J Biol Chem       Date:  1980-03-25       Impact factor: 5.157

7.  Possible role for calmodulin in calcium paradox-induced heart failure.

Authors:  S W Schaffer; R S Roy; J M McMcord
Journal:  Eur Heart J       Date:  1983-12       Impact factor: 29.983

Review 8.  Calmodulin plays a pivotal role in cellular regulation.

Authors:  W Y Cheung
Journal:  Science       Date:  1980-01-04       Impact factor: 47.728

9.  Beta-adrenoceptor antagonists and the release of creatine phosphokinase from hypoxic heart muscle.

Authors:  W G Nayler; A Grau; C Yepez
Journal:  Cardiovasc Res       Date:  1977-07       Impact factor: 10.787

10.  Effect of locally released catecholamines on lipolysis and injury of the hypoxic isolated rabbit heart.

Authors:  E Karwatowska-Kryńska; A Beresewicz
Journal:  J Mol Cell Cardiol       Date:  1983-08       Impact factor: 5.000

View more
  2 in total

1.  Anti-ischemic and membrane stabilizing activity of calmodulin inhibitors.

Authors:  A Beresewicz
Journal:  Basic Res Cardiol       Date:  1989 Nov-Dec       Impact factor: 17.165

2.  Amiodarone is a potent calmodulin antagonist.

Authors:  P Nokin; J P Blondiaux; P Schaeffer; L Jungbluth; C Lugnier
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-04       Impact factor: 3.000

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.